| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2011-06-16 | Cevec (Germany) Catalent Pharma Solutions (USA) | Cell line development services | collaboration |
Collaboration agreement | ||
| 2011-06-16 | Gentium (Italy) Gen Ilac (Turkey) | defibrotide | distribution |
Digestive diseases | Distribution agreement | |
| 2011-06-15 | Bavarian Nordic (Denmark) Danish Defence (Denmark) | Imvamune® | smallpox | Delivery |
Infectious diseases | Services contract |
| 2011-06-15 | Gentium (Italy) Link Pharmaceuticals (Australia) | defibrotide | treatment and prevention of hepatic veno-occlusive disease (VOD) in haematopoietic stem-cell transplantation therapy, in adults and children | distribution |
Digestive diseases - Liver diseases - Transplantation | Distribution agreement |
| 2011-06-14 | Sartorius Stedim Biotech (France) Südpack Medica (Germany) | polymer plastic films for the biopharmaceutical market | development |
Development agreement | ||
| 2011-06-14 | Antitope (UK) IMMIH-University of Cologne (Germany) | monoclonal therapeutic antibodies for use in polyvalent vaccines against antibiotic-resistant bacterial infections | R&D |
Infectious diseases | R&D agreement | |
| 2011-06-14 | Arecor (UK) GSK (UK) | advanced formulations of vaccines combining Arecor’s unique formulation technologies with GSK’s proprietary vaccines | licensing |
Licensing agreement | ||
| 2011-06-13 | Kareus Therapeutics (Switzerland) Quintiles (USA) | two pre-clinical programs including KU-046, a first-in-class new chemical entity discovered by Kareus for the treatment of Alzheimer\'s disease | Alzheimer's disease - type 2 diabetes | development |
Neurodegenerative diseases - Metabolic diseases | Development agreement |
| 2011-06-09 | Novagali Pharma (France) Ardeo Health (USA) OCuSOFT (USA) | Nova23041 | distribution |
Ophtalmological diseases | Distribution agreement | |
| 2011-06-09 | Isconova (Sweden) Crucell (J&J subsidiary - the Netherlands USA) | Isconova’s adjuvant Matrix M™ | HIIV, malaria | licensing |
Infectious diseases - Parasitic diseases | Licensing agreement |
| 2011-06-08 | Asterand (UK) Capsant Neurotechnologies (UK) | isletOrganDOT™ | Diabetes | Licensing | Metabolic diseases | |
| 2011-06-08 | Merck KGaA, Merck Serono (Germany) Affectis Pharmaceuticals (Germany) | oral compounds targeting P2X7 receptors | Neurological diseases | development commercialisation |
CNS diseases | Development agreement |
| 2011-06-07 | Erytech Pharma (France) Teva Pharmaceuticals (Israel) | Graspa® (asparaginase encapsulated into red blood cells) | registration |
Cancer - Oncology | Commercialisation agreement | |
| 2011-06-07 | Oxford BioMedica (UK) ImaginAb (USA - CA) | in vivo diagnostic imaging agent using an antibody targeting Oxford Biomedica’s proprietary 5T4 tumour antigen | solid tumours | R&D |
Cancer - Oncology | R&D agreement |
| 2011-06-07 | Pharming Group (Netherlands) MegaPharm (Israel) | Ruconest® (Rhucin® in non-European territories - conestat alfa) | acute angioedema attacks in patients with Hereditary Angioedema (HAE) | commercialisation |
Rare diseases | Commercialisation agreement |
| 2011-06-07 | Antitope (UK) NasVax (Israel) | monoclonal therapeutic antibodies for the treatment of inflammatory and autoimmune diseases | R&D |
Inflammatory diseases - Autoimmune diseases | R&D agreement | |
| 2011-06-06 | Cellectis (France) VitamFero (France) | living attenuated vaccines | parasite infections | R&D development licensing |
Infectious diseases | Licensing agreement |
| 2011-06-06 | Cellectis (France) Vitamfero (France) | meganuclease technology for the design and development of a new generation of living attenuated vaccines. | R&D |
Veterinary medicine | Licensing agreement | |
| 2011-06-02 | Evotec (Germany) Active Biotech (Sweden) | small molecule modulators of a priority biological target | R&D |
Immune diseases - Cancer | R&D agreement | |
| 2011-06-02 | BMS (USA) Roche (Switzerland) | Yervoy® (ipilimumab), in combination with Roche’s investigational oral BRAF inhibitor, vemurafenib | metastatic melanoma | R&D |
Cancer - Oncology | R&D agreement |
